Avenue Therapeutics, Inc. ATXI
0.50
0.14
38.89%
as of 24 Sep
- Market cap
- $680.0K
- P/E
- 0.0×
Follow ATXI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | — | — | — | — | — | — |
P/S ratio |
0.00 | — | — | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | — | — | — | — | — | — | — | — | — |
P/Operating CF |
(2.49) | — | — | — | — | — | — | — | — | — |
P/B ratio |
1.16 | — | — | — | — | — | — | — | — | — |
Price to Tangible BV |
1.16 | — | — | — | — | — | — | — | — | — |
EV/Sales |
0.00 | — | — | — | — | — | — | — | — | — |
EV/EBITDA |
0.11 | — | — | — | — | — | — | — | — | — |
EV/Operating CF |
0.18 | — | — | — | — | — | — | — | — | — |
EV/FCF |
0.18 | — | — | — | — | — | — | — | — | — |
Quick Ratio |
2.60 | 3.18 | 1.49 | 1.87 | 7.57 | 3.54 | 4.13 | 0.52 | 7.81 | 0.03 |
Current Ratio |
2.67 | 3.27 | 1.55 | 1.91 | 7.78 | 3.66 | 4.22 | 0.88 | 7.95 | 0.03 |
Net Debt/EBITDA |
0.93 | 0.23 | 0.12 | 0.83 | 1.01 | 0.60 | 0.33 | 0.12 | 1.94 | (0.81) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,028.43% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.25) |
Asset Turnover |
0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.63 | 0.77 | 0.91 | 2.14 | 1.01 | 0.90 | 1.01 | 0.85 | 0.55 | 0.51 |
Capex/Depreciation |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (157.75%) | (928.45%) | (529.44%) | (105.76%) | (128.43%) | (112.48%) | (839.94%) | (229.86%) | (220.23%) | 47.48% | |
| (103.84%) | (515.35%) | (238.69%) | (65.75%) | (103.57%) | (84.72%) | (385.54%) | (161.44%) | (109.61%) | (3,011.37%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(158.79%) | (627.80%) | (1,586.70%) | (108.76%) | (108.11%) | (218.36%) | (381.00%) | 3,414.90% | (63.25%) | 51.06% |
Average Days of Receivables |
0.00 | — | — | — | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
73.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
260.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
47.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.86 | — | — | — | — | — | — | — | — | — |
Graham Number |
0.00 | — | — | — | — | — | — | — | — | — |
Earnings Yield |
(138.24%) | — | — | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(86.09%) | — | — | — | — | — | — | — | — | — |
Revenue per Share |
0.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.59) | (6.97) | (67.03) | (261.03) | (248.34) | (315.96) | (1,889.14) | (2,001.76) | (1,152.88) | (652.80) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.59) | (6.97) | (67.03) | (261.03) | (248.34) | (315.96) | (1,889.14) | (2,001.76) | (1,152.88) | (652.80) |
Cash per Share |
0.91 | 2.00 | 12.65 | 230.52 | 249.21 | 214.52 | 629.14 | 293.52 | 3,691.86 | 78.80 |
Shareholders Equity per Share |
0.59 | 1.43 | 4.64 | 112.23 | 228.54 | 161.58 | 489.21 | (69.34) | 3,284.75 | (3,299.20) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.59 | 1.43 | 4.64 | 112.23 | 228.54 | 161.58 | 489.21 | (69.34) | 3,284.75 | (3,299.20) |
Free Cash Flow |
(1.83) | (9.03) | (9.45) | (7.60) | (3.75) | (4.61) | (26.26) | (18.22) | (6.80) | (1.63) |
Working Capital |
1.83 | 1.86 | 0.65 | 3.27 | 3.45 | 2.36 | 6.80 | (0.63) | 19.38 | (6.22) |
Net Current Asset Value |
1.83 | 1.86 | 0.65 | 3.27 | 3.45 | 2.36 | 6.80 | (0.63) | 19.38 | (8.25) |
EV/EBIT |
0.11 | — | — | — | — | — | — | — | — | — |
Capex to Sales |
0.00 | — | — | — | — | — | — | — | — | — |
Net Profit Margin |
(207.19%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | — | — | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | — | — | — | — | — | — | 0.00 | 0.00 |
Cash ROIC |
(39.11%) | (202.83%) | (387.81%) | (76.16%) | (51.98%) | (84.01%) | (168.92%) | (892.94%) | (16.52%) | 27.09% |
Accounts Receivable Turnover |
0.00 | — | — | — | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
0.95 | 0.71 | 0.79 | 0.74 | 0.70 | 0.99 | 2.89 | 3.70 | 1.62 | 0.50 |
Average Assets |
2.80 | 2.26 | 4.35 | 5.40 | 3.60 | 6.08 | 6.72 | 13.35 | 11.18 | 0.11 |
Average Common Equity |
1.84 | 1.26 | 1.96 | 3.36 | 2.91 | 4.58 | 3.08 | 9.37 | 5.57 | (6.69) |
Columns are period end dates